- Exchange: NASDAQ CM
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Snapshot for GenVec Inc (GNVC)
| Open: | 2.4600 | Day's Range: | 2.4599 - 2.5200 | Volume: | 46,700 | Bid: | 2.5000 |
|---|---|---|---|---|---|---|---|
| Previous Close: | 2.5000 | 52wk Range: | 2.0000 - 3.5400 | 1-Yr Rtn: | -24.78% | Ask: | 2.5200 |
Key Statistics for GNVC
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E (12/2012) | - |
| Earnings Per Share (USD) (ttm) | -0.6500 |
| Est. EPS (USD) (12/2012) | -0.6700 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 32.65 |
| Shares Outstanding (M) | 12.96 |
| Enterprise Value (M USD) (ttm) | 8.50 |
| Enterprise Value/EBITDA (ttm) | - |
| Price/Book (mrq) | 1.3790 |
| Price/Sale (ttm) | 2.0850 |
| Dividend Indicated Gross Yield | 0.0000 |
| Next Earnings Announcement | 08/09/2012 |
More GNVC Key Statistics
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Financials for GNVC
- Operating
- Investing
- Financing (M/USD)
Company Profile & Key Executives for GNVC
GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. The Company specializes in the treatment of cancers, including pancreatic cancer, esophageal cancer, rectal caner, and head and neck cancer. The Company is also involved in studies involving hearing loss and balance disorders. GenVec also develops vaccines for infectious diseases.
| Zola P HorovitzChairman | Cynthia CollinsPresident/CEO |
| Douglas J SwirskySenior VP/CFO/Treasurer/Secy | Bryan T ButmanSenior VP:Vector Operations |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Links
Top Forex Trading Resources
Advertisement
Advertisement
Advertisements
Rate this Page